Skip to content

H.R. 8333 · 118th Congress (2023–2025)

BIOSECURE Act

This bill prohibits entities that receive federal funds from using biotechnology that is from a company associated with a foreign adversary.

Specifically, federal agencies and recipients of federal funds (e.g., grantees) may not procure or use any biotechnology equipment or service that is from a biotechnology company of concern and may not contract with any entities that do so. A biotechnology company of concern is an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information).

The Office of Management and Budget (OMB) must, in coordination with the Department of Defense (DOD) and other specified agencies, develop a list of prohibited companies; the list must include five particular companies, as specified in the bill. OMB and DOD may approve waivers of these restrictions on an as-needed basis, which are valid for up to one year and may be extended once for an additional 180 days.

In addition, the Office of the Director of National Intelligence must report on the national security risks posed by (1) multiomic data collection by foreign adversaries in connection with biotechnology equipment or services, and (2) biotechnology companies that have such data.

Show official title

To prohibit contracting with certain biotechnology providers, and for other purposes.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

122 days after it was introduced

This is H.R. 8333’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced4 months

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Brad R. Wenstrup (R-OH-2)
Cosponsors
14 cosponsors

7 original · 7 later

7 R · 7 D

  1. Rep. Donald G. Davis (D-NC-1)· Original · May 10, 2024
  2. Rep. Neal P. Dunn (R-FL-2)· Original · May 10, 2024
  3. Rep. Anna G. Eshoo (D-CA-16)· Original · May 10, 2024
  4. Rep. Raja Krishnamoorthi (D-IL-8)· Original · May 10, 2024
  5. Rep. John R. Moolenaar (R-MI-2)· Original · May 10, 2024
  6. Rep. Seth Moulton (D-MA-6)· Original · May 10, 2024
  7. Rep. Elise M. Stefanik (R-NY-21)· Original · May 10, 2024
  8. Rep. Ashley Hinson (R-IA-2)· Later · May 14, 2024
  9. Rep. Elissa Slotkin (D-MI-7)· Later · May 14, 2024
  10. Rep. Stephanie I. Bice (R-OK-5)· Later · May 21, 2024
  11. Rep. Josh Gottheimer (D-NJ-5)· Later · May 21, 2024
  12. Rep. Darin LaHood (R-IL-16)· Later · Jul 8, 2024
  13. Rep. Thomas R. Suozzi (D-NY-3)· Later · Jul 8, 2024
  14. Rep. Mark E. Green (R-TN-7)· Later · Sep 9, 2024
Policy area
Health
Subjects
  • Asia
  • China
  • Congressional oversight
  • Diplomacy, foreign officials, Americans abroad
  • Foreign and international corporations
  • Government employee pay, benefits, personnel management
  • Government information and archives
  • Government lending and loan guarantees
  • 3 more
    • Government studies and investigations
    • Health technology, devices, supplies
    • Public contracts and procurement

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. ▸ 3 committee actions · May 10, 2024 – May 15, 2024
    1. Referred to committee

      Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    3. Ordered reported

      Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.

      Sources
  3. Passed House

    Roll call 402

    Congressional Record H5051–H5052

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402).

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources
  4. Latest

    Referred to committee

    Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

    Sources
  5. Expired

    Passed House → Referred to Senate Homeland Security and Governmental Affairs → No further action before the 118th Congress ended.

Roll-call votes

  1. House roll call 402Passed

    On Motion to Suspend the Rules and Pass, as Amended

    306–81

Committees

  1. HouseIntelligence (Permanent Select)Referred May 10, 2024
  2. HouseOversight and AccountabilityReferred May 10, 2024 · Markup May 15, 2024
    1. May 15, 2024 · Markup

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Sep 9, 2024 · House · Considered under suspension of the rulesCongressional Record H5051–H5058

    Biosecure Act

  2. Sep 9, 2024 · House · Considered as unfinished businessCongressional Record H5081–H5082

    Biosecure Act

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Engrossed in House
Referred in Senate
Titles (2)
  1. BIOSECURE Act

    Short title, Display title · Referred in Senate, Engrossed in House, Introduced in House

  2. To prohibit contracting with certain biotechnology providers, and for other purposes.

    Official title · Introduced in House